Original Article

Frequency of Anti-Toxoplasma gondii IgM and IgG and the Associ-ated Risk Factors in Patients with Breast Cancer: A Case-Control Study

Abstract

Background: Toxoplasma gondii is an obligate intracellular parasite capable of causing serious disease, especially among individuals with compromised immunity, including those undergoing cancer treatment. Approximately one-third of the global population is infected with. gondii. The present investigation evaluated the prevalence of anti-T. gondii IgM and IgG antibodies and explored related risk factors in breast cancer patients compared with healthy controls.
Methods: Between Oct 2023 and Feb 2024, serum samples were obtained from 167 women, including 111 with breast cancer and 56 healthy controls. Anti-T. gondii IgM and IgG antibodies were measured through ELISA. Structured questionnaires were employed to record demographic profiles and relevant exposure factors. Data were statistically processed using chi-square, t-test, and logistic regression modeling.
Results: Overall, the IgG antibody was positive in 48.6% of the cases with breast cancer and 33.9% of the control group. However, the groups had similar mean T. gondii IgG antibody titers, with no significant differences. Moreover, the IgM antibody tests were negative in both groups. Our results show a high seropositivity rate for toxoplasmosis in age groups over 50 yr old. No meaningful correlations were identified between seropositivity and other factors such as dietary habits, contact with animals, or history of blood transfusion.
Conclusion: Anti-T. gondii IgG seropositivity was higher among breast cancer patients than controls, but the association was not statistically significant after adjustment for potential confounders. These findings do not provide sufficient evidence of an association between T. gondii seropositivity and breast cancer. Further studies with larger sample sizes are warranted to clarify this relationship.

1. Hamidi F, Rostami A, Hosseini SA, et al. Anti-Toxoplasma gondii IgG seroprevalence in the general population in Iran: A systematic review and meta-analysis, 2000–2023. PLoS One. 2024;19(8):e0307941.
2. Al-Malki ES. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci. 2021;28(1):962-9.
3. Strube C, Raue K, Janecek E. Simple, but not easy–Opportunities and challenges from teachers’ and students’ perspectives in the 21st century of veterinary parasitology teaching. Vet Parasitol. 2018;252:74-9.
4. Shojaee S, Teimouri A, Keshavarz H, et al. The relation of secondary sex ratio and miscarriage history with Toxoplasma gondii infection. BMC Infect Dis. 2018;18(1):307.
5. Kalantari R, Esmaeilifallah M, Jafari R, et al. A large-scale study on the seroprevalence of Toxoplasma gondii infection in humans in Iran. Folia Parasitol. 2023;70:2023.004.
6. Ali-Heydari S, Keshavarz H, Shojaee S, Mohebali M. Diagnosis of antigenic markers of acute toxoplasmosis by IgG avidity immunoblotting. Parasite. 2013;20:18.
7. Pazoki H, Mirjalali H, Niyyati M, et al. Toxoplasma gondii profilin induces NLRP3 activation and IL-1β production/secretion in THP-1 cells. Microb Pathog. 2023;180:106120.
8. Daher D, Shaghlil A, Sobh E, et al. Comprehensive overview of Toxoplasma gondii-induced and associated diseases. Pathogens. 2021;10(11):1351.
9. Pazoki H, Ziaee M, Anvari D, et al. Toxoplasma gondii infection as a potential risk for chronic liver diseases: A systematic review and meta-analysis. Microb Pathog. 2020;149:104578.
10. Robert-Gangneux F, Dardé M-L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264-96.
11. Teimouri A, Goudarzi F, Goudarzi K, et al. Toxoplasma gondii Infection in Immunocompromised Patients in Iran (2013-2022): A Systematic Review and Meta-Analysis. Iran J Parasitol. 2022;17(4):443-57.
12. Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217-22.
13. Bashar MDA, Begam N. Breast cancer surpasses lung cancer as the most commonly diagnosed cancer worldwide. Indian J Cancer. 2022;59(3):438-9.
14. Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021;41(11):1183-94.
15. Anvari D, Sharif M, Sarvi S, Aghayan SA, et al. Seroprevalence of Toxoplasma gondii infection in cancer patients: a systematic review and meta-analysis. Microb Pathog. 2019;129:30-42.
16. Haghbin M, Maani S, Bagherzadeh MA, et al. Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran. Int J Breast Cancer. 2023;2023:4792260.
17. Soltani S, Foroutan M, Ghaderi S, Karimi M. Seroprevalence of Toxoplasma gondii Infection in Cancer Patients in Southwest Iran: A Case-Control Study. Compr Health Biomed Stud. 2024;3(2):e157368.
18. Ali OA, khudair Khalaf A. The Potential Role of Toxoplasma gondii Infection in Breast Cancer Through Affecting Programmed Death-1 Genes: Role of Toxoplasma gondii Infection in BC. Arch Breast Cancer. 2024;11(4):400-7.
19. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken (NJ): John Wiley & Sons; 2013.
20. Alvarado-Esquivel C, Maldonado-Soto E, Sanchez-Anguiano LF, et al. Lack of serological and molecular association between Toxoplasma gondii exposure and obesity: a case-control study. Int J Biomed Sci. 2017;13(2):74-8.
21. Ali MI, Abd El Wahab WM, Hamdy DA, Hassan A. Toxoplasma gondii in cancer patients receiving chemotherapy: seroprevalence and interferon gamma level. J Parasit Dis. 2019;43(3):464-471.
22. Ahmadpour E, Daryani A, Sharif M, et al. Toxoplasmosis in immunocomprom-ised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries. 2014;8(12):1503-10.
23. Ye H, Zhou X, Zhu B, et al. Toxoplasma gondii suppresses proliferation and migration of breast cancer cells by regulating their transcriptome. Cancer Cell Int. 2024;24(1):144.
24. Liu L, Wang P, Xu J, Xia C-M. Increased risk of Toxoplasma gondii infection in cancer patients: A meta-analysis of current evidence based on case-control study. Acta Trop. 2019;192:30-40.
25. Barzinij AKRA. Seroprevalence and risk factors of toxoplasmosis among University of Kirkuk female students. Ann Parasitol. 2021;67(2):175-186.
26. Mohammed LO, Amin AM, Mohammed RM, et al. Seroprevalence of Anti-Toxoplasma gondii Antibodies among Patients with Cancer at Hiwa Cancer Hospital in Sulaimani City, Kurdistan Region, Iraq. Iran J Parasitol. 2023;18(4):526-534.
Files
IssueVol 21 No 4 (2026) QRcode
SectionOriginal Article(s)
Keywords
Toxoplasma gondii Breast cancer Seroprevalence Risk factors mmunocompromised patients

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ebrahimi M, Nazar E, Rostami A, Mirjalali H, Taghdiri A, Pazoki H. Frequency of Anti-Toxoplasma gondii IgM and IgG and the Associ-ated Risk Factors in Patients with Breast Cancer: A Case-Control Study. Iran J Parasitol. 2026;21(4):488-497.